Do analysts recommend PTHL or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, PTHL or MBAI?

Check-Cap has lower revenue, but higher earnings than Pheton. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 7.33 -$660K N/A N/A Check-Cap N/A N/A $4.14M -$2.77 N/A

Is PTHL or MBAI more profitable?

Company Net Margins Return on Equity Return on Assets Pheton N/A N/A N/A Check-Cap N/A N/A N/A

Do analysts recommend QNRX or PTHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, QNRX or PTHL?

Pheton has higher revenue and earnings than Quoin Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quoin Pharmaceuticals N/A N/A -$15.81M -$29.56 N/A Pheton $305.22K 7.33 -$660K N/A N/A

Is QNRX or PTHL more profitable?

Pheton's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Quoin Pharmaceuticals N/A -489.85% -221.29% Pheton N/A N/A N/A

Do analysts prefer VVOS or PTHL?

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 410.95%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, VVOS or PTHL?

Pheton has lower revenue, but higher earnings than Vivos Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vivos Therapeutics $17.44M 0.44 -$21.17M -$2.14 N/A Pheton $305.22K 7.33 -$660K N/A N/A

Do analysts recommend PTHL or SINT?

Sintx Technologies has a consensus price target of $9.33, indicating a potential upside of 325.21%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sintx Technologies is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation & earnings, PTHL or SINT?

Pheton has higher earnings, but lower revenue than Sintx Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 7.33 -$660K N/A N/A Sintx Technologies $1.02M 9.30 -$10.36M -$5.07 N/A

Do analysts rate PTHL or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PTHL or NXL?

Pheton has higher revenue and earnings than Nexalin Technology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 7.33 -$660K N/A N/A Nexalin Technology $275.58K 30.99 -$8.22M -$0.47 N/A

Pheton (PTHL) Competitors

$0.34 -0.06 (-16.03%)

As of 06/12/2026

Compare

PTHL vs. MBAI, QNRX, VVOS, SINT, and NXL

Should you buy Pheton stock or one of its competitors? MarketBeat compares Pheton with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pheton include Check-Cap (MBAI), Quoin Pharmaceuticals (QNRX), Vivos Therapeutics (VVOS), Sintx Technologies (SINT), and Nexalin Technology (NXL). These companies are all part of the "medical equipment" industry.

How does Pheton compare to Check-Cap?

Pheton (NASDAQ:PTHL) and Check-Cap (NASDAQ:MBAI) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Check-Cap has lower revenue, but higher earnings than Pheton.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	7.33	-$660K	N/A	N/A
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A

1.1% of Check-Cap shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Check-Cap	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has a beta of 5.4, meaning that its share price is 440% more volatile than the broader market. Comparatively, Check-Cap has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

In the previous week, Check-Cap had 3 more articles in the media than Pheton. MarketBeat recorded 3 mentions for Check-Cap and 0 mentions for Pheton. Check-Cap's average media sentiment score of 1.21 beat Pheton's score of 0.00 indicating that Check-Cap is being referred to more favorably in the news media.

Company	Overall Sentiment
Pheton	Neutral
Check-Cap	Positive

Summary

Check-Cap beats Pheton on 5 of the 7 factors compared between the two stocks.

How does Pheton compare to Quoin Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has higher revenue and earnings than Quoin Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Pheton	$305.22K	7.33	-$660K	N/A	N/A

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Pheton. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 0 mentions for Pheton. Quoin Pharmaceuticals' average media sentiment score of 1.43 beat Pheton's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Quoin Pharmaceuticals	Positive
Pheton	Neutral

Pheton's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Pheton	N/A	N/A	N/A

Quoin Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the broader market. Comparatively, Pheton has a beta of 5.4, indicating that its share price is 440% more volatile than the broader market.

Summary

Quoin Pharmaceuticals beats Pheton on 6 of the 11 factors compared between the two stocks.

How does Pheton compare to Vivos Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Vivos Therapeutics had 13 more articles in the media than Pheton. MarketBeat recorded 13 mentions for Vivos Therapeutics and 0 mentions for Pheton. Vivos Therapeutics' average media sentiment score of 0.50 beat Pheton's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Vivos Therapeutics	Neutral
Pheton	Neutral

Pheton has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -127.70%. Pheton's return on equity of 0.00% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Pheton	N/A	N/A	N/A

Vivos Therapeutics has a beta of 6.1, suggesting that its stock price is 510% more volatile than the broader market. Comparatively, Pheton has a beta of 5.4, suggesting that its stock price is 440% more volatile than the broader market.

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 410.95%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

26.4% of Vivos Therapeutics shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pheton has lower revenue, but higher earnings than Vivos Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.44	-$21.17M	-$2.14	N/A
Pheton	$305.22K	7.33	-$660K	N/A	N/A

Summary

Vivos Therapeutics beats Pheton on 9 of the 14 factors compared between the two stocks.

How does Pheton compare to Sintx Technologies?

Pheton (NASDAQ:PTHL) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, Sintx Technologies had 2 more articles in the media than Pheton. MarketBeat recorded 2 mentions for Sintx Technologies and 0 mentions for Pheton. Sintx Technologies' average media sentiment score of 1.16 beat Pheton's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Pheton	Neutral
Sintx Technologies	Positive

Pheton has higher earnings, but lower revenue than Sintx Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	7.33	-$660K	N/A	N/A
Sintx Technologies	$1.02M	9.30	-$10.36M	-$5.07	N/A

Pheton has a beta of 5.4, meaning that its share price is 440% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Pheton has a net margin of 0.00% compared to Sintx Technologies' net margin of -1,058.60%. Pheton's return on equity of 0.00% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

Sintx Technologies has a consensus price target of $9.33, indicating a potential upside of 325.21%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Sintx Technologies is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

18.4% of Sintx Technologies shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Sintx Technologies beats Pheton on 9 of the 14 factors compared between the two stocks.

How does Pheton compare to Nexalin Technology?

Pheton (NASDAQ:PTHL) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Pheton has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Pheton's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

Pheton has a beta of 5.4, indicating that its share price is 440% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.8, indicating that its share price is 280% more volatile than the broader market.

0.6% of Nexalin Technology shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Nexalin Technology had 5 more articles in the media than Pheton. MarketBeat recorded 5 mentions for Nexalin Technology and 0 mentions for Pheton. Nexalin Technology's average media sentiment score of 0.85 beat Pheton's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Pheton	Neutral
Nexalin Technology	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has higher revenue and earnings than Nexalin Technology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	7.33	-$660K	N/A	N/A
Nexalin Technology	$275.58K	30.99	-$8.22M	-$0.47	N/A

Summary

Pheton beats Nexalin Technology on 6 of the 11 factors compared between the two stocks.

Get Pheton News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTHL vs. The Competition

Export

Metric	Pheton	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.24M	$8.65B	$6.48B	$12.36B
Dividend Yield	N/A	1.71%	2.67%	5.66%
P/E Ratio	N/A	23.72	23.95	24.60
Price / Sales	7.33	22.60	536.37	171.61
Price / Cash	N/A	13.73	27.48	37.92
Price / Book	0.36	5.57	10.44	6.77
Net Income	-$660K	$174.80M	$3.56B	$337.32M
7 Day Performance	21.43%	1.81%	0.83%	2.06%
1 Month Performance	9.32%	9.98%	1.78%	3.93%
1 Year Performance	-98.03%	6.09%	25.59%	32.29%

Pheton Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTHL Pheton	N/A	$0.34 -16.0%	N/A	-98.0%	$2.24M	$305.22K	N/A	11	Gap Down
MBAI Check-Cap	0.9471 of 5 stars	$1.33 -5.0%	N/A	N/A	$10.20M	N/A	N/A	80	Short Interest Decrease
QNRX Quoin Pharmaceuticals	1.5765 of 5 stars	$5.06 +2.2%	N/A	-49.9%	$9.94M	N/A	N/A	4	Analyst Forecast Short Interest Decrease Gap Down
VVOS Vivos Therapeutics	3.7331 of 5 stars	$0.64 -8.8%	$2.80 +338.3%	-73.3%	$9.73M	$17.44M	N/A	160	Positive News
SINT Sintx Technologies	3.5987 of 5 stars	$2.07 -3.7%	$9.33 +350.9%	-35.2%	$9.29M	$1.02M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTHL) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pheton (PTHL) Competitors

PTHL vs. MBAI, QNRX, VVOS, SINT, and NXL

How does Pheton compare to Check-Cap?

Summary

How does Pheton compare to Quoin Pharmaceuticals?

Summary

How does Pheton compare to Vivos Therapeutics?

Summary

How does Pheton compare to Sintx Technologies?

Summary

How does Pheton compare to Nexalin Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pheton (PTHL) Competitors

PTHL vs. MBAI, QNRX, VVOS, SINT, and NXL

How does Pheton compare to Check-Cap?

Which has preferable earnings and valuation, PTHL or MBAI?

Do institutionals & insiders hold more shares of PTHL or MBAI?

Is PTHL or MBAI more profitable?

Do analysts recommend PTHL or MBAI?

Which has more risk & volatility, PTHL or MBAI?

Does the media favor PTHL or MBAI?

Summary

How does Pheton compare to Quoin Pharmaceuticals?

Do institutionals and insiders have more ownership in QNRX or PTHL?

Do analysts recommend QNRX or PTHL?

Which has higher earnings and valuation, QNRX or PTHL?

Does the media prefer QNRX or PTHL?

Is QNRX or PTHL more profitable?

Which has more risk and volatility, QNRX or PTHL?

Summary

How does Pheton compare to Vivos Therapeutics?

Does the media refer more to VVOS or PTHL?

Is VVOS or PTHL more profitable?

Which has more risk and volatility, VVOS or PTHL?

Do analysts prefer VVOS or PTHL?

Do insiders & institutionals hold more shares of VVOS or PTHL?

Which has preferable earnings & valuation, VVOS or PTHL?

Summary

How does Pheton compare to Sintx Technologies?

Does the media refer more to PTHL or SINT?

Which has stronger valuation & earnings, PTHL or SINT?

Which has more risk and volatility, PTHL or SINT?

Is PTHL or SINT more profitable?

Do analysts recommend PTHL or SINT?

Do insiders and institutionals have more ownership in PTHL or SINT?

Summary

How does Pheton compare to Nexalin Technology?

Is PTHL or NXL more profitable?

Which has more risk and volatility, PTHL or NXL?

Do insiders & institutionals believe in PTHL or NXL?

Does the media favor PTHL or NXL?

Do analysts rate PTHL or NXL?

Which has stronger earnings & valuation, PTHL or NXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools